A precipitous step deeper into the CDMO business
23/11/20 -"Wacker's Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production of CureVac's COVID-19 vaccine candidate is being ..."
Pages
58
Language
English
Published on
23/11/20
You may also be interested by these reports :
29/06/25
We have incorporated the latest figures and anticipate another challenging year for the company, with no division acting as a significant drag. While ...
27/06/25
The divesture of the Indian decorative paints is a well done deal, but the funds will not be well allocated. While we appreciate the deleveraging, we ...
25/06/25
The global economic uncertainties have increased recently, influenced by President Trump’s trade war and the escalation of the Israeli-Iranian ...
03/06/25
We view the divestment of Catalyst Technologies as a strategic misstep, although we acknowledge that Johnson Matthey’s (JM) current focus is on free ...